2026年晚期前列腺癌共识会议:高危局限、局部晚期及生化复发前列腺癌管理投票结果
2026年APCCC会议通过改良Delphi流程制定134个高危局限/局部晚期前列腺癌相关问题,由133名专家投票,以≥75%为共识阈值,44题(32.8%)达成共识,其中7题获强共识(≥90%),结果可辅助临床决策并识别证据空白。
要点
- 共识阈值预设为≥75%同意,强共识为≥90%同意。
- 134个问题中44个(32.8%)达成共识,7个达强共识。
- 投票结果不包含正式文献回顾或Meta分析。
核心结论
- 投票结果有助于医患在证据稀少或矛盾的争议领域进行临床管理决策。
- 结果可帮助资助者和政策制定者优先确定未来研究方向。
- APCCC 2026识别出需专门试验评估的无共识重要空白领域。
研究设计与样本
- 会前由144名国际前列腺癌专家多学科小组通过改良Delphi流程制定313个多选题共识问题。
- 其中134个问题涉及高危局限和局部晚期前列腺癌,包括PSA持续存在、PSA复发及治疗副作用。
- 133名投票小组委员在会前通过网络调查完成投票。
主要发现
- 134个问题中44个(32.8%)达成共识。
- 7个问题达到强共识。
- 投票结果显示不同程度的共识,详见本文及补充材料。
关键数值与推荐
- 共识定义为预先设定的≥75%同意。
- 强共识定义为≥90%同意。
临床怎么用
- 投票结果可帮助医生和患者在证据匮乏或矛盾的争议领域导航临床管理。
- 结果可帮助资助者和政策制定者优先安排未来研究领域。
局限性
- 这些发现不包括正式文献回顾或Meta分析。
- 存在无共识的重要空白领域,需专门设计的试验评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Innovations have improved outcomes in high-risk localised, locally advanced, and biochemically recurrent prostate cancer (PC), yet high-level evidence remains limited for many management decisions. The 2026 Advanced Prostate Cancer Consensus Conference (APCCC) surveyed an international panel on key clinical questions to complement evidence-based guidelines. OBJECTIVE: Here we present the voting results for the questions on high-risk localised, locally advanced, and biochemically recurrent PC from APCCC 2026. DESIGN, SETTING, AND PARTICIPANTS: Before the conference, a multidisciplinary panel of 144 international PC experts used a modified Delphi process to develop 313 multiple-choice consensus questions, of which 134 covered high-risk localised and locally advanced PC, including prostate-specific antigen (PSA) persistence and PSA recurrence, and side effects of treatment. These questions were administered to the 133 voting panel members "panellists" via a web-based survey prior to the conference. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Consensus was defined a priori as ≥75% agreement, with strong consensus defined as ≥90% agreement. Overall, consensus was reached for 44 of the 134 questions (32.8%), with seven questions reaching a strong consensus. Results and limitations The voting results show varying degrees of consensus, as discussed in this article and as detailed in the Supplementary Material. An interactive heat map for the questions can be found at https://apccc.org/APCCC2026-votings-localised-and-locally-advanced-prostate-cancer/. These findings do not include a formal literature review or meta-analysis. CONCLUSIONS: The voting results can help physicians and patients navigate controversial areas of clinical management for which evidence is scant or conflicting. The findings can also help funders and policymakers in prioritising areas for future research. Importantly, APCCC 2026 once again identified important gaps (areas of no consensus) that merit evaluation in specifically designed trials.
引用
- Gillessen, Turco, Davis, et al. Management of Patients with High-risk Localised, Locally Advanced, and Biochemically Recurrent Prostate Cancer: Report from the 2026 Advanced Prostate Cancer Consensus Conference. Eur Urol. 2026. PMID: 42934071. doi:10.1016/j.eururo.2026.09.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。